Skip to main content

Immix Biopharma, Inc.

corporate_fare Company Profile

Immix Biopharma, Inc.

IMMX·NASDAQ·Life Sciences·CIK 0001873835

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company incorporated in Delaware on January 7, 2014. The company focuses on developing cell therapies for AL Amyloidosis and specific immune-mediated diseases. In August 2016, Immix Biopharma established a wholly-owned Australian subsidiary, Immix Biopharma Australia Pty Ltd. (IBAPL), to conduct preclinical and clinical activities for its development candidates. In November 2022, the company formed Nexcella, Inc., a majority-owned subsidiary and its cell therapy division. Nexcella subsequently merged into Immix Biopharma, Inc. in May 2024, with Immix Biopharma, Inc. continuing as the surviving entity. The company's fiscal year ends on December 31.

Immix Biopharma, Inc. (NASDAQ:IMMX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for IMMX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Immix Biopharma Files $750M Shelf Registration, Signaling Substantial Future Dilution

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$29.44M
Diluted EPS
-$0.89
Op. Cash Flow
-$23.93M
Free Cash Flow
-$24.66M
Operating Income
-$29.96M
Cash & Equivalents
$93.93M
Debt / Equity
0.00×
Shares Outstanding
52.95M sh
Source: 10-K · filed 2026-03-27 · accession 0001493152-26-013298
$7.21 +2.41% today
52-week range · as of 2026-11-12 $3.26 – $15.1
Market cap
$583.33M
Volume
1.6M (1.3× avg)
3-mo avg 1.2M
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IMMX - Filings & News (Page 2)

IMMX
Jan 09, 2026, 5:28 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $4.78
Real-time Price: $7.21 info
Change: +$2.43 (+51%) info
Market Cap: $583.335M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets